

Rhonda M Cooper-Dehoff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4884197/publications.pdf>

Version: 2024-02-01

96
papers

2,729
citations

257101

24
h-index

197535

49
g-index

97
all docs

97
docs citations

97
times ranked

4394
citing authors

#	ARTICLE	IF	CITATIONS
1	Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 61.	3.8	578
2	Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 181-191.	1.1	213
3	Hypertension Across a Woman's Life Cycle. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1797-1813.	1.2	159
4	The Clinical Pharmacogenetics Implementation Consortium Guideline for <i>SLCO1B1</i> , <i>ABCG2</i> , and <i>CYP2C9</i> genotypes and Statin-Associated Musculoskeletal Symptoms. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1007-1021.	2.3	120
5	Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In practice (IGNITE) network. <i>BMC Medical Genomics</i> , 2017, 10, 35.	0.7	99
6	Hypertension pharmacogenomics: in search of personalized treatment approaches. <i>Nature Reviews Nephrology</i> , 2016, 12, 110-122.	4.1	90
7	Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. <i>Journal of Hypertension</i> , 2014, 32, 635-643.	0.3	88
8	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 534-543.	5.5	84
9	2014 Eighth Joint National Committee Panel Recommendation for Blood Pressure Targets Revisited. <i>Journal of the American College of Cardiology</i> , 2014, 64, 784-793.	1.2	67
10	Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome. <i>Journal of Women's Health</i> , 2016, 25, 875-881.	1.5	65
11	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021, 42, 1742-1756.	1.0	63
12	Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated With Antihypertensive Medications. <i>Hypertension</i> , 2010, 55, 61-68.	1.3	60
13	Branched-chain amino acid, meat intake and risk of type 2 diabetes in the Women's Health Initiative. <i>British Journal of Nutrition</i> , 2017, 117, 1523-1530.	1.2	60
14	Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial. <i>American Heart Journal</i> , 2021, 237, 90-103.	1.2	51
15	Cardiovascular Therapies and Associated Glucose Homeostasis. <i>Journal of the American College of Cardiology</i> , 2009, 53, S28-S34.	1.2	47
16	Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to β -Blockers in Hypertensive African Americans. <i>Hypertension</i> , 2016, 67, 556-563.	1.3	41
17	INVEST revisited: review of findings from the International Verapamil SR-Transdolapril Study. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1329-1340.	0.6	36
18	Vascular Smooth Muscle Cells From Hypertensive Patient-Derived Induced Pluripotent Stem Cells to Advance Hypertension Pharmacogenomics. <i>Stem Cells Translational Medicine</i> , 2015, 4, 1380-1390.	1.6	36

#	ARTICLE	IF	CITATIONS
19	Genome-wide study of resistant hypertension identified from electronic health records. PLoS ONE, 2017, 12, e0171745.	1.1	36
20	Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide. Hypertension, 2017, 69, 51-59.	1.3	34
21	Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: An ancillary study of the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. American Heart Journal, 2014, 167, 826-832.	1.2	33
22	Large-Scale Gene-Centric Analysis Identifies Polymorphisms for Resistant Hypertension. Journal of the American Heart Association, 2014, 3, e001398.	1.6	32
23	Association between high sensitivity C-reactive protein and metabolic syndrome in subjects completing the National Health and Nutrition Examination Survey (NHANES) 2009-10. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2014, 8, 88-90.	1.8	25
24	Long-Term Mortality in Hypertensive Patients With Coronary Artery Disease. Hypertension, 2016, 68, 1110-1114.	1.3	25
25	How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial. Clinical Pharmacology and Therapeutics, 2020, 108, 557-565.	2.3	24
26	A Genetic Response Score for Hydrochlorothiazide Use. Hypertension, 2016, 68, 621-629.	1.3	21
27	Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β -Blockers. Journal of the American Heart Association, 2018, 7, .	1.6	18
28	Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network. Genetics in Medicine, 2021, 23, 1185-1191.	1.1	17
29	Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS ONE, 2021, 16, e0248080.	1.1	17
30	Blood pressure lowering in patients with diabetes-one level might not fit all. Nature Reviews Cardiology, 2011, 8, 42-49.	6.1	16
31	Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. American Journal of Medicine, 2018, 131, 1463-1472.e7.	0.6	16
32	Genome-wide association analysis of common genetic variants of resistant hypertension. Pharmacogenomics Journal, 2019, 19, 295-304.	0.9	16
33	The PCORnet Blood Pressure Control Laboratory. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006115.	0.9	16
34	Genetic loci associated with nonobstructive coronary artery disease in Caucasian women. Physiological Genomics, 2016, 48, 12-20.	1.0	15
35	Genetic Variants Associated With Uncontrolled Blood Pressure on β -Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials. Journal of the American Heart Association, 2017, 6, .	1.6	15
36	Hypertension in Florida: Data From the OneFlorida Clinical Data Research Network. Preventing Chronic Disease, 2018, 15, E27.	1.7	15

#	ARTICLE	IF	CITATIONS
37	Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering. <i>Journal of Clinical Hypertension</i> , 2019, 21, 825-834.	1.0	15
38	Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol. <i>Metabolomics</i> , 2016, 12, 1.	1.4	14
39	Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. <i>Journal of Women's Health</i> , 2016, 25, 996-1003.	1.5	14
40	Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals. <i>Hypertension</i> , 2019, 74, 614-622.	1.3	14
41	Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease. <i>Journal of Clinical Hypertension</i> , 2019, 21, 91-101.	1.0	14
42	Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis. <i>American Journal of Medicine</i> , 2019, 132, 172-174.	0.6	14
43	Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 131, 93-98.	1.9	13
44	Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across <i>CYP2D6</i> Genotype-Derived Activity Scores. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 678-685.	1.3	13
45	Calcium antagonists in the treatment of coronary artery disease. <i>Current Opinion in Pharmacology</i> , 2013, 13, 301-308.	1.7	12
46	Optimizing identification of resistant hypertension: Computable phenotype development and validation. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1393-1401.	0.9	12
47	Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. <i>Cardio-Oncology</i> , 2021, 7, 10.	0.8	12
48	Optimizing Antihypertensive Medication Classification in Electronic Health Record-Based Data: Classification System Development and Methodological Comparison. <i>JMIR Medical Informatics</i> , 2020, 8, e14777.	1.3	12
49	Tracking Blood Pressure Control Performance and Process Metrics in 25 US Health Systems: The PCORnet Blood Pressure Control Laboratory. <i>Journal of the American Heart Association</i> , 2021, 10, e022224.	1.6	12
50	Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension. <i>Journal of Clinical Hypertension</i> , 2017, 19, 1301-1308.	1.0	11
51	Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease. <i>Cardiovascular Endocrinology</i> , 2015, 4, 45-52.	0.8	10
52	Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. <i>Metabolomics</i> , 2016, 12, 1.	1.4	10
53	New Drug Approvals in 2018 – Another Record Year!. <i>American Journal of Medicine</i> , 2019, 132, 1038-1043.	0.6	10
54	Generic Drugs for Hypertension: Are They Really Equivalent?. <i>Current Hypertension Reports</i> , 2013, 15, 340-345.	1.5	9

#	ARTICLE	IF	CITATIONS
55	β ₂ -Adrenergic Receptor Gene Affects the Heart Rate Response of β-Blockers: Evidence From 3 Clinical Studies. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1462-1470.	1.0	9
56	Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension. <i>American Journal of Hypertension</i> , 2019, 32, 668-675.	1.0	9
57	Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension. <i>American Journal of Hypertension</i> , 2016, 29, 1186-1194.	1.0	8
58	Attended vs unattended systolic blood pressure measurement: A randomized comparison in patients with cardiovascular disease. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1987-1992.	1.0	8
59	Sorting nexin 1 loss results in increased oxidative stress and hypertension. <i>FASEB Journal</i> , 2020, 34, 7941-7957.	0.2	8
60	Impact of Aspirin According to Type of Stable Coronary Artery Disease: Insights from a Large International Cohort. <i>American Journal of Medicine</i> , 2015, 128, 137-143.	0.6	7
61	Multiplex SNaPshot™ a new simple and efficient CYP2D6 and ADRB1 genotyping method. <i>Human Genomics</i> , 2016, 10, 11.	1.4	7
62	Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. <i>PLoS ONE</i> , 2019, 14, e0221957.	1.1	7
63	New Drugs Approved in 2019. <i>American Journal of Medicine</i> , 2020, 133, 675-678.	0.6	7
64	Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients. <i>Metabolites</i> , 2021, 11, 645.	1.3	7
65	New Drugs Approved in 2021. <i>American Journal of Medicine</i> , 2022, , .	0.6	7
66	Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. <i>BMC Medical Genomics</i> , 2018, 11, 55.	0.7	6
67	Multi-Institutional Implementation of Clinical Decision Support for APOL1, NAT2, and YEATS4 Genotyping in Antihypertensive Management. <i>Journal of Personalized Medicine</i> , 2021, 11, 480.	1.1	6
68	Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 723-732.	2.3	6
69	Intensive blood pressure lowering reduces adverse cardiovascular outcomes among patients with high-normal glucose: An analysis from the Systolic Blood Pressure Intervention Trial database. <i>Journal of Clinical Hypertension</i> , 2018, 20, 620-624.	1.0	5
70	Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease. <i>Journal of Hypertension</i> , 2018, 36, 419-427.	0.3	5
71	Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting. <i>American Journal of Hypertension</i> , 2020, 33, 316-324.	1.0	5
72	Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure. <i>ESC Heart Failure</i> , 2020, 7, 124-130.	1.4	5

#	ARTICLE	IF	CITATIONS
73	Potential of Minocycline for Treatment of Resistant Hypertension. <i>American Journal of Cardiology</i> , 2021, 156, 147-149.	0.7	5
74	Effects of Verapamil SR and Atenolol on 24-Hour Blood Pressure and Heart Rate in Hypertension Patients with Coronary Artery Disease: An International Verapamil SR-Trandolapril Ambulatory Monitoring Substudy. <i>PLoS ONE</i> , 2015, 10, e0122726.	1.1	4
75	Objectively measured pediatric obesity prevalence using the OneFlorida Clinical Research Consortium. <i>Obesity Research and Clinical Practice</i> , 2019, 13, 12-15.	0.8	4
76	Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 363-369.	1.1	3
77	2017 Is Banner Year for Drug Approvals by the Food and Drug Administration. <i>American Journal of Medicine</i> , 2018, 131, 1025-1033.	0.6	3
78	Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone. <i>American Journal of Medicine</i> , 2021, 134, 918-925.e2.	0.6	3
79	New Drugs Approved in 2020. <i>American Journal of Medicine</i> , 2021, 134, 1096-1100.	0.6	3
80	Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and COVID-19-related outcomes: A patient-level analysis of the PCORnet blood pressure control lab. <i>American Heart Journal Plus</i> , 2022, 13, 100112.	0.3	3
81	Redefining Resistant Hypertension. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e005979.	0.9	2
82	Assessment of a Manual Method versus an Automated, Probability-Based Algorithm to Identify Patients at High Risk for Pharmacogenomic Adverse Drug Outcomes in a University-Based Health Insurance Program. <i>Journal of Personalized Medicine</i> , 2022, 12, 161.	1.1	2
83	Serotonin Transporter Gene Polymorphism in Women With Suspected Ischemia. , 2018, 2, 8-15.	0.8	1
84	Atherosclerotic cardiovascular disease risk assessment and predictors of statin use in Filipino-American Women. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 632-639.	0.7	1
85	Optimal systolic blood pressure and reduced long-term mortality in older hypertensive women with prior coronary events – An analysis from INVEST-†. <i>International Journal of Cardiology: Hypertension</i> , 2020, 7, 100052.	2.2	1
86	Optimizing Precision of Hypertension Care to Maximize Blood Pressure Control: A Pilot Study Utilizing a Smartphone App to Incorporate Plasma Renin Activity Testing. <i>Clinical and Translational Science</i> , 2021, 14, 617-624.	1.5	1
87	Acetaminophen-Induced Hypertension: Where Have All the ‘Safe’ Analgesics Gone?. <i>Circulation</i> , 2022, 145, 424-426.	1.6	1
88	Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study. <i>Genes</i> , 2022, 13, 1260.	1.0	1
89	Ethnicity and blood pressure control in patients with diabetes and coronary artery disease. <i>American Journal of Hypertension</i> , 2002, 15, A194.	1.0	0
90	Response to Letter by Barrios and Escobar. <i>Stroke</i> , 2009, 40, .	1.0	0

#	ARTICLE	IF	CITATIONS
91	The use of diuretics plus calcium channel blockers for hypertension may be associated with a higher risk of myocardial infarction but not stroke compared with the combination of diuretics plus A^{\wedge} blockers. Evidence-Based Medicine, 2010, 15, 92-93.	0.6	0
92	Home blood pressure monitoring with patient-initiated drug titration reduces blood pressure in high-risk patients with hypertension. Evidence-Based Medicine, 2015, 20, 58-58.	0.6	0
93	Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence. American Journal of Hypertension, 2020, 33, e2-e2.	1.0	0
94	Implications of Polymorphisms in the BCKDK and GATA $\text{A}^{\wedge}4$ Gene Regions on Stable Warfarin Dose in African Americans. Clinical and Translational Science, 2021, 14, 492-496.	1.5	0
95	Abstract 15465: Precision Medicine Approach to Resistant Hypertension: Genetic Markers of Resistant Hypertension Through a Genome-wide Association Study (GWAS) in the Secondary Prevention of Subcortical Strokes (SPS3). Circulation, 2015, 132, .	1.6	0
96	Abstract 15986: Plasma MicroRNA Profiling Reveals Potential Biomarkers of Thiazide Response. Circulation, 2020, 142, .	1.6	0